Medicamen Biotech Limited (IN:MEDICAMEQ)

:MEDICAMEQ

MEDICAMEQ

Medicamen Biotech Limited

RESEARCH TOOLSreports

Want to see IN:MEDICAMEQ full AI Analyst Report?

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹220.00 - ₹456.20

Previous CloseN/A

Volume10.37K

Average Volume (3M)2.40K

Market Cap

₹3.48B

Enterprise Value₹3.37B

Total Cash (Recent Filing)₹436.79M

Total Debt (Recent Filing)₹386.49M

Price to Earnings (P/E)56.5

Beta1.47

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.26%

Share Statistics

EPS (TTM)1.61

Shares Outstanding13,562,815

10 Day Avg. Volume3,620

30 Day Avg. Volume2,395

Financial Highlights & Ratios

PEG Ratio-2.50

Price to Book (P/B)2.95

Price to Sales (P/S)3.86

P/FCF Ratio-52.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Stable Balance Sheet And Moderate LeverageA reasonable debt-to-equity ratio, solid equity ratio and satisfactory ROE indicate long-term solvency and capital efficiency. This durable financial structure supports investment in manufacturing capacity, helps absorb industry cycles, and preserves access to external capital when needed.

Healthy EBIT/EBITDA MarginsRelatively healthy operating margins point to effective cost control in formulation manufacturing. Durable margin strength provides a buffer against revenue swings, funds routine reinvestment, and supports competitiveness in low-margin generic and specialty drug segments.

Domestic And Export Formulation BusinessSales across domestic and international markets diversify revenue sources and reduce single-market exposure. Export capability signals regulatory compliance and scale potential, creating a structural advantage versus purely local peers and supporting longer-term revenue resilience.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erodes financial flexibility and forces reliance on external funding for capex, working capital, or growth. Over months this can constrain product launches, capacity expansion, and increase financing costs if not reversed.

Inconsistent Revenue GrowthA negative and inconsistent top-line trend limits predictability for production planning and undermines capacity utilization. Over a multi-month horizon, weak revenue momentum hampers ability to scale operations, invest in new products, and maintain steady margin improvement.

Volatile Net Profit MarginVolatile net margins reduce earnings visibility and complicate long-term budgeting. For a manufacturing-focused pharma firm, margin swings may reflect pricing pressure or input-cost variability, making strategic investments and dividend or debt servicing plans less reliable.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

2M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹220.00 and its highest was ₹456.20 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.48B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Jun 03, 2026 which is in 36 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Feb 13, 2026. The company reported ₹1.613 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.613.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.26%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.613 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.671%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.